Glucotrack (GCTK) adds Lokahi merger statements and pro forma results

Lōkahi Therapeutics, a subsidiary of Glucotrack (GCTK), has initiated GMP manufacturing for LT-100, a honeybee-venom-derived biologic for osteoarthritis pain. The company aims to transition from 15 intradermal injections to a single subcutaneous injection per visit. GMP production is a key step in advancing LT-100 through clinical and regulatory milestones, with the first patient enrollment expected later this year, according to the company.

Glucotrack, Inc. (GCTK) filed an 8-K saying that on Aug. 4, 2026 it arranged follow-on financing totaling $5.5M through a $3.5M bridge follow-on and an interim PIPE. The bridge follow-on issued $3.5M senior secured convertible notes at 8% interest, with 22% OID, plus warrants, subject to stockholder approval for conversion and exercise.

Glucotrack Inc. said it raised about $5.5 million through institutional financing, including a $2.0 million equity investment priced at $0.75 per unit (share plus 5-year warrant at $1.50) and $3.5 million in follow-on convertible debt. The company plans to use proceeds to fund its implantable continuous blood glucose monitoring program and biopharmaceutical platform via Lōkahi Therapeutics.

Today's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.

GlucoTrack (NASDAQ:GCTK) shares rose more than 70% after hours after the company said nonclinical minipig data support its LT-100 program using one subcutaneous injection per visit for knee osteoarthritis pain, replacing up to 15 intradermal injections. The update follows an FDA Type C meeting in May 2026, with clinical evaluation starting as early as Q4 2026 and readout in H1 2027.

Healthcare stocks moved on multiple FDA and EU updates. Novartis (NVS) won FDA approval for Fabhalta in IgA nephropathy; Merck (MRK) got FDA nod for LIPFENDRA and KEYTRUDA+Padcev in bladder cancer; Novo Nordisk (NVO) received EU approval for oral Wegovy. Lilly (LLY) agreed to buy AtaiBeckley for $6.75/share plus up to $2.50 CVR.